Study of OL-CD19-GDT for hard-to-treat autoimmune diseases
Part of Skin clinical trials.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with either systemic sclerosis or Sjögren's syndrome that has not improved with at least one standard treatment.
- Your disease is active and affects at least one major organ besides the skin (for systemic sclerosis) or you have a certain level of disease activity (for Sjögren's).
- You are generally in good health aside from your autoimmune disease, with no serious infections, heart problems, or other uncontrolled conditions.
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control for 2 years after treatment.
- You have not had CAR-T cell therapy before and are not using other experimental treatments currently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
This study tests a new investigational drug (called ATG-201) for people with autoimmune diseases. It aims to see if the drug is safe and how it works in the body.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.